Pfizer breaks AHA pre-conference rules on data disclosure
Pharma Compliance Alert, November 15, 2006
The American Heart Association cancelled a presentation of new data on Pfizer's cholesterol drug Torcetrapib scheduled for its annual meeting because the company released information about the data two weeks ago, according to The Wall Street Journal.
Torcetrapib raises so-called "good cholesterol, but also appears to also raise blood pressure. On October 30, the company issued a press release explaing that the drug raised systolic blood pressure an average of three to four millimeters of mercury, according to the latest analysis, whereas previous studies had shown an increase of two to three millimeters of mercury. Normal systolic blood pressure is 120 millimeters of mercury.
The results were to have been presented November 15 at the AHA annual meeting currently being held in Chicago.
According to WSJ, a Pfizer spokesman said the company issued the news release last month because of the high level of interest among doctors and investors in the torcetrapib program. Pfizer plans to present the data instead during a review of the company's research and development pipeline on Nov. 30.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q&A tackles coding questions about injections and infusions
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- Case Management Monthly, June 2012
- Searched